(function(){ var content_array=["

关于诺和诺德<\/b><\/p> \n

诺和诺德公司成立于1923年，是一家全球领先的生物制药公司，总部位于丹麦。立足于在糖尿病领域的百年传承，我们的使命是驱动改变，携手战胜严重慢性疾病。为达成这一目标，我们引领科研突破，扩大公司药物可及性，并致力于预防及最终治愈疾病。诺和诺德在全球80个国家和地区拥有约7.84万名员工，向全球约170个国家和地区提供产品和服务。诺和诺德<\/span>中国官方网站：http:\/\/www.novonordisk.com.cn<\/a><\/p> \n

免责声明<\/b><\/p> \n

本新闻稿仅用于传递相关前沿科学信息和市场资讯。本新闻稿不构成对任何药物或治疗方案的推荐、推广或广告。读者不应参考、依据或依赖本新闻稿的任何内容，作出购买、使用任何药物或治疗方案的任何决定。如读者有药物或治疗方面的问题，请咨询医疗卫生专业人士。<\/p> \n

本新闻稿含有关于诺和诺德产品的前瞻性信息，该等信息的有效性仅截至其发布日期。诺和诺德无义务就由于新信息、未来事件、事件进展或其他原因产生的任何变化对相关信息进行更新。对于因使用、依赖本新闻稿中包含的任何信息或任何信息遗漏而直接或间接产生的任何损失，诺和诺德不承担任何责任。<\/p> \n

在转发、使用或以其它方式处理本新闻稿中的信息前，相关行为人应负责确保其行为符合所有相关国家或司法管辖区的任何适用法律、法规和监管要求。任何由于引用、转载、编辑或通过其它方式使用本新闻稿中所含信息而产生的一切直接或间接的后果，均由相关行为人自行承担全部责任，诺和诺德不对此承担任何责任。建议相关行为人在转发、使用或以其它方式处理本新闻稿中的信息前审慎评估风险，必要时请咨询专业法律人士的意见。<\/p> \n

特此声明。<\/p> \n

\n \n \n \n

_______________________
参考文献<\/b><\/span><\/p>

1.     Wilson L, Zhao Z, Divino V, et al<\/i>. Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice. Oral presentation at the European Society of Cardiology Congress 2025; 29 August–01 September 2025; IFEMA Madrid, Madrid, Spain.<\/span><\/p>

2.     World Heart Federation. World Heart Report 2023: Confronting the World's Number One Killer. Available at: https:\/\/world-heart-federation.org\/wp-content\/uploads\/World-Heart-Report-2023.pdf<\/a>. Last accessed: July 2025.<\/span><\/p>

3.     Haidar A and Horwich T. Obesity, Cardiorespiratory Fitness, and Cardiovascular Disease. Curr Cardiol Rep<\/i>. 2023;25:1565–1571.<\/span><\/p>

4.     Zizza C, Herring AH, Stevens J, et al.<\/i> Length of Hospital Stays Among Obese Individuals. Am J Public Health<\/i>. 2004;94:1587–1591.<\/span><\/p>

5.     Raisi-Estabragh Z, Kobo O, Mieres JH, et al.<\/i> Racial Disparities in Obesity-Related Cardiovascular Mortality in the United States: Temporal Trends From 1999 to 2020. J Am Heart Assoc<\/i>. 2023;12: e028409.<\/span><\/p>

6.     Collaborators GBDO, Afshin A, Forouzanfar MH, et al<\/i>. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med<\/i>. 2017;377:13–27.<\/span><\/p>

7.     Blonde L, Khunti K, Harris SB, et al<\/i>. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Adv Ther<\/i>. 2018;35:1763–1774.<\/span><\/p>

8.     Lincoff AM, Brown-Frandsen K, Colhoun HM, et al<\/i>. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med<\/i>. 2023;389:2221–2232.<\/span><\/p>

9.     Zhao Z, Song J, Faurby M, et al<\/i>. Lower Risk of MACE and All-Cause Death in Patients Initiated on Semaglutide 2.4 mg in Routine Clinical Care: Results from the SCORE Study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World). Moderated poster presentation at the American College of Cardiology Scientific Session & Expo 2025; 29–31 March 2025; McCormick Place Convention Center, Chicago, US. Presentation 947-13.<\/span><\/p>

10.   Wegovy®<\/sup> Summary of Product Characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/wegovy-epar-product-information_en.pdf<\/a>. Last accessed: August 2025.<\/span><\/p>

11.   Wegovy®<\/sup> Prescrib information. Avaialble at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/215256s015lbl.pdf<\/a>. Last accessed: August 2025.<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div>"]; $("#dvExtra").html(content_array[0]);})();